Methotrexate Pfizer Indications/Uses

The following are representative indications. Locally approved indications may differ.
Methotrexate is a cytotoxic drug used for antineoplastic chemotherapy and in certain nonmalignant conditions.
Anti-neoplastic Chemotherapy: Methotrexate is indicated for the treatment of gestational choriocarcinoma, and in patients with chorioadenoma destruens and hydatidiform mole.
Methotrexate is indicated for the palliation of acute lymphocytic leukemia. It is also indicated in the treatment and prophylaxis of meningeal leukemia. Greatest effect has been observed in palliation of acute lymphoblastic (stem-cell) leukemias in children. In combination with other anticancer drugs or suitable agents Methotrexate may be used for induction of remission, but it is most commonly used, as described in the monograph, in the maintenance of induced remissions.
Methotrexate may be used alone or in combination with other anticancer agents in the management of breast cancer, epidermoid cancers of the head and neck, and lung cancer, particularly squamous cells and small cell types.
Methotrexate is also effective in the treatment of the advanced stages (III and IV, Peters Staging System) of lymphosarcoma, particularly in those cases in children; and in advanced cases of mycosis fungoides.
Psoriasis Chemotherapy (See Precautions): Because of high risk attending its use, Methotrexate is only indicated in the symptomatic control of severe, recalcitrant, disabling psoriasis which is not adequately responsive to other forms of therapy, but only when the diagnosis has been established, as by biopsy and/or after dermatologic consultation.
Rheumatoid arthritis.